Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BIOCORP : won CPhI Pharma Awards 2017

share with twitter share with LinkedIn share with facebook
10/27/2017 | 12:08pm EDT
Press Release BIOCORP won CPhI Pharma Awards 2017, in the "IT, mHealth and Digitalisation" category, for its entire connected devices range ISSOIRE, France, October 27th, 2017 (6:00 PM CEST) - BIOCORP (FR0012788065 - ALCOR / PEAPME eligible), a

French company specializing in the development and manufacturing of medical devices and smart-drug delivery systems,

announces today that it won the CPhI Pharma Awards 20171 in the "IT, mHealth and Digitalization" category, thanks to its range of connected devices. The event took place on October 24 at the Intercontinental Hotel in Frankfurt, Germany.

Created in 2004 by CPhI Worldwide2, CPhI Pharma Awards are one of the most prestigious award of the pharmaceutical industry. Presented during CPhI Worldwide exhibition, these awards recognize each year innovators' excellence and new thinkers who are committed to advancing the industry.

This internationally recognized pharmaceutical show, organized in collaboration with ICSE, Innopack, P-MEC and FDF, welcomes more than 42,000 professionals of the sector and 2,500 exhibitors from 153 countries. This event allows participants to establish new business relationships, to meet international partners and learn about the latest trends in the industry. Each sector of the pharmaceutical market was represented at this fair, which took place on October 2017, from 24th to 26th in Frankfurt, Germany.

This international competition, which received more than 200 entries for the 2017 edition, distinguished winners in 19 categories. BIOCORP has distinguished itself as a true innovator in connected medicine, winning the first prize in the "IT, mHealth and Digitalization" category with its range of connected devices. BIOCORP has demonstrated the excellence and the degree of technology thanks to its Inspair sensor (intelligent sensor that transforms a conventional inhaler into a connected and communicating device) or its DataPen (reusable and communicating pen-injector).

"We are thrilled to receive this CPhI Pharma trophy, one of the most prestigious in the pharmaceutical industry. This award represents a new recognition of BIOCORP expertise and excellence in the field of connected medicine, which is more than ever at the heart of our innovation policy. This award, presented in the presence of pharmaceutical sector key players but also of our peers, once again underlines our ability to develop innovative devices geared towards patients, with the ultimate goal of better therapeutic follow-up ", comments Eric Dessertenne, Deputy Chief Executive Officer of BIOCORP."


Founded in 2004 in Issoire (near Clermont-Ferrand), France, BIOCORP is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as 'Innovative Company' by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, BIOCORP is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, BIOCORP continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 48 employees.

BIOCORP is listed on Alternext since July 2015 (FR0012788065 - ALCOR). For more information, please visit: www.biocorp.fr

Follow us on Twitter @BIOCORPSystems


2 https://www.cphi.com/europe/



Jacques Gardette

Président Directeur Général investisseurs@biocorp.fr

Eric Dessertenne Directeur Général Délégué

Relations presse ALIZE RP

Caroline Carmagnol & Wendy Rigal 01 44 54 36 66 - 06 48 82 18 94


Biocorp Production SA published this content on 27 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 October 2017 16:07:09 UTC.

share with twitter share with LinkedIn share with facebook
Latest news on BIOCORP
06/30BIOCORP : Signs Distribution Agreement for Mallya Technology With Roche Diabetes..
06/22BIOCORP : Announces Initiation of Coverage by Gilbert Dupont
06/19BIOCORP : and Théa Sign a Partnership for the Development of Innovative Digital ..
04/09BIOCORP : 2019 annual results
04/09BIOCORP : 2019 Annual Results
04/09BIOCORP : Annual results
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
02/12BIOCORP : Strong Revenue Growth In 2019
More news
Sales 2020 15,2 M 17,2 M 17,2 M
Net income 2020 0,60 M 0,68 M 0,68 M
Net cash 2020 1,19 M 1,34 M 1,34 M
P/E ratio 2020 175x
Yield 2020 0,06%
Capitalization 109 M 122 M 122 M
EV / Sales 2019
EV / Sales 2020 7,04x
Nbr of Employees 52
Free-Float 51,3%
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 31,35 €
Last Close Price 26,30 €
Spread / Highest target 21,7%
Spread / Average Target 19,2%
Spread / Lowest Target 16,7%
EPS Revisions
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG4.71%295 898
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-10.36%192 057
PFIZER, INC.-11.92%191 697